ArticleTranslational psychiatry2021
Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence.
Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis.Molecular psychiatry · 2026Review
- Cell-type and spatiotemporal transcriptional signatures of white matter morphometric similarity network alterations in major depressive disorder.Psychological medicine · 2026Article
- Dynamic interactions between gut microbiome and host lipidome in antenatal depression: a large longitudinal study.Molecular psychiatry · 2026Article
- Transformations in plasma metabolic profiles of patients with major depression disorder during treatment.Metabolic brain disease · 2025Article
- Perceived indoor annoyances at home and risk of incident depression: A Danish register-based cohort study, 2000-2018.Environmental epidemiology (Philadelphia, Pa.) · 2025Article
- Article
- Pharmaceutical Studies on Piperazine-based Compounds Targeting Serotonin Receptors and Serotonin Reuptake Transporters.Mini reviews in medicinal chemistry · 2025Review
- Flavins and Flavoproteins in the Neuroimmune Landscape of Stress Sensitization and Major Depressive Disorder.Journal of inflammation research · 2025Review
- Vitamin-mediated interaction between the gut microbiome and mitochondria in depression: A systematic review-based integrated perspective.Brain, behavior, & immunity - health · 2024Review
- Article
- Metabolic features of treatment-refractory major depressive disorder with suicidal ideation.Translational psychiatry · 2023Article
- Downregulated NPAS4 in multiple brain regions is associated with major depressive disorder.Scientific reports · 2023Article
- Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research.Molecules (Basel, Switzerland) · 2023Review
- Plasma lipidomic profile of depressive symptoms: a longitudinal study in a large sample of community-dwelling American Indians in the strong heart study.Molecular psychiatry · 2023Article
- The antidepressant-like effect of guanosine involves the modulation of adenosine APurinergic signalling · 2023Article
- Lipids in major depressive disorder: new kids on the block or old friends revisited?Frontiers in psychiatry · 2023Review
- Article
- Review
- Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?Frontiers in neuroscience · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD in remission. We used an established LC-MS/MS platform to measure 399 metabolites in 68 subjects with rMDD (n = 45 females and 23 males) in antidepressant-free remission and 59 age- and sex-matched controls (n = 40 females and 19 males). Patients were then followed prospectively for 2.5 years. Metabolomics explained up to 43% of the phenotypic variance. The strongest biomarkers were gender specific. 80% of the metabolic predictors of recurrence in both males and females belonged to 6 pathways: (1) phospholipids, (2) sphingomyelins, (3) glycosphingolipids, (4) eicosanoids, (5) microbiome, and (6) purines. These changes traced to altered mitochondrial regulation of cellular redox, signaling, energy, and lipid metabolism. Metabolomics identified a chemical endophenotype that could be used to stratify rrMDD patients at greatest risk for recurrence with an accuracy over 0.90 (95%CI = 0.69-1.0). Power calculations suggest that a validation study of at least 198 females and 198 males (99 cases and 99 controls each) will be needed to confirm these results. Although a small study, these results are the first to show the potential utility of metabolomics in assisting with the important clinical challenge of prospectively identifying the patients at greatest risk of recurrence of a depressive episode and those who are at lower risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.